A new generation of vaccines within animal health

Intervacc AB is a Swedish company active in the biotechnology sector. We develop new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care, with a very good safety profile.

Together with our two subsidiaries Nordvacc Läkemedel and the Mybac-Vettech Laboratory, we strive to strengthen animal health and welfare. Here you can find more about the Group’s products and services and our vaccine candidate against equine strangles, Strangvac ®, the first of the new generation of vaccines.

  • Intervacc’s subsidiary company Nordvacc have over 30 years’ experience in the veterinary vaccines market, serving the Nordic, Dutch and Baltic markets with more than 200 million doses sold
  • The technology platform is based on research from the Karolinska Institute and the Swedish University of Agricultural Sciences
  • Strangles

    a highly contagious infectious horse disease lacking adequate vaccine protection

Introduce Investor Days

Intervacc participated in Introduce Investor Day on December 5, 2019 at Haymarket in Stockholm. CEO Andreas Andersson presented the company and the development of a new generation of animal health vaccines that interested a large number of listeners and not least all those who followed the event via the live broadcast.

Here you can see the recorded presentation which is about 25 minutes including the following Q&A.